Efficacy and safety of oxaliplatin and capecitabine in combination with sintilimab as first-line treatment for HER2-negative advanced gastric cancer
"<b>Objective</b> To analyze the clinical efficacy and the occurrence of adverse events of the oxaliplatin and capecitabine (XELOX) combined with sintilimab as a first-line treatment in patients with human epidermal growth factor receptor2 (HER2)-negative advanced gastric cancer(GC). <b>Methods</b...
Αποθηκεύτηκε σε:
| Κύριος συγγραφέας: | |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Chinês |
| Έκδοση: |
The Editorial Department of Chinese Journal of Clinical Research
2025-01-01
|
| Σειρά: | Zhongguo linchuang yanjiu |
| Θέματα: | |
| Διαθέσιμο Online: | http://zglcyj.ijournals.cn/zglcyj/ch/reader/create_pdf.aspx?file_no=20250108&year_id=2025&quarter_id=1&falg=1 |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|